Curia Executive and Leadership Team

Philip Macnabb, the Chief Executive Officer at Curia, directs the overarching corporate strategy and global business operations. Overseeing the transition from R&D to commercial manufacturing, the Chief Executive Officer ensures alignment across all service lines to meet the complex needs of pharmaceutical clients. Philip Macnabb drives the expansion of manufacturing capabilities, focusing on scaling production capacity to support life-saving drug development. By fostering collaboration between research teams and commercial units, the Chief Executive Officer optimizes the end-to-end value chain. This leadership role involves navigating the competitive landscape of contract development and manufacturing organizations while maintaining rigorous quality standards. Through the implementation of long-term growth initiatives, Macnabb secures the market position of the firm. The Chief Executive Officer prioritizes operational efficiency and client satisfaction, ensuring that the organization remains a preferred partner for biopharmaceutical companies seeking reliable, high-quality development and manufacturing support across international markets.

Alex Milenkovic, the Founder & Chief Executive Officer at Curia, architects the foundational vision and long-term strategic direction of the organization. Focusing on the integration of advanced research methodologies with large-scale manufacturing, the Founder & Chief Executive Officer drives the evolution of the company service portfolio. Alex Milenkovic oversees the development of proprietary technologies that enhance drug discovery and production efficiency for global pharmaceutical partners. By aligning corporate objectives with emerging industry trends, the Founder & Chief Executive Officer ensures the firm maintains a competitive edge in the biopharmaceutical sector. This leadership role involves cultivating strategic partnerships and guiding the executive team toward sustainable growth targets. Through the continuous refinement of business models, Milenkovic supports the delivery of high-value solutions from early-stage R&D through commercialization. The Founder & Chief Executive Officer champions a culture of scientific rigor and innovation, positioning the organization as a critical link in the global pharmaceutical supply chain.

James Grabowski, the President, Research & Development at Curia, directs the scientific strategy and early-stage development services provided to pharmaceutical clients. Overseeing the laboratory operations and research teams, the President, Research & Development ensures the delivery of high-quality data and innovative solutions for complex drug discovery programs. James Grabowski architects the technical roadmap for expanding research capabilities, focusing on novel therapeutic modalities and advanced screening technologies. By collaborating with commercial manufacturing leaders, the President, Research & Development facilitates the smooth transition of projects from the laboratory to large-scale production. This leadership role involves managing scientific talent and maintaining the highest standards of research excellence to meet client expectations. Through the optimization of R&D workflows, Grabowski drives the efficiency and success rate of drug development initiatives. The President, Research & Development supports the growth of the firm by positioning the research division as a leader in providing critical insights and development services to the global biopharmaceutical market.

Ronald Aungst, the President, Drug Product at Curia, directs the commercial manufacturing and drug product formulation operations. Overseeing the production facilities and supply chain logistics, the President, Drug Product ensures the reliable delivery of high-quality pharmaceutical products to global customers. Ronald Aungst architects strategies to optimize manufacturing throughput and maintain strict adherence to regulatory quality standards. By managing the integration of new production technologies, the President, Drug Product enhances the capacity to handle complex drug formulations and sterile manufacturing requirements. This leadership role involves coordinating with R&D teams to ensure the scalability of new products and meeting the rigorous demands of commercial-scale production. Through the continuous improvement of manufacturing processes, Aungst drives operational excellence and cost-efficiency. The President, Drug Product supports the overall business mission by ensuring that the organization provides consistent, high-quality manufacturing services that meet the critical needs of pharmaceutical and biopharmaceutical partners worldwide.

Kourtney Forster, the President at Curia, directs the strategic execution of business initiatives and oversees the operational performance of key service divisions. Focusing on the alignment of cross-functional teams, the President ensures that the organization delivers integrated solutions from research through commercial manufacturing. Kourtney Forster architects business development strategies that expand the market reach and strengthen relationships with major biopharmaceutical clients. By monitoring operational metrics and financial performance, the President drives efficiency and supports the achievement of corporate growth targets. This leadership role involves collaborating with the executive team to navigate market challenges and capitalize on emerging opportunities in the pharmaceutical services sector. Through the implementation of streamlined management processes, Forster enhances the agility and responsiveness of the firm. The President maintains a focus on delivering superior value to customers by ensuring that all operational units work in concert to provide seamless, high-quality support for drug development and manufacturing projects.

Joseph Sangregorio, the Chief Human Resources Officer at Curia, directs the global talent strategy and organizational development initiatives. Overseeing the recruitment, retention, and professional growth of a diverse scientific and manufacturing workforce, the Chief Human Resources Officer ensures the company attracts top-tier talent to support complex pharmaceutical projects. Joseph Sangregorio architects comprehensive programs that foster employee engagement and align individual performance with corporate goals. By implementing robust training and development frameworks, the Chief Human Resources Officer strengthens the technical capabilities of the staff across all operational sites. This leadership role involves managing organizational culture and ensuring compliance with international labor standards while supporting the rapid scaling of business operations. Through the optimization of human capital management, Sangregorio directly impacts the productivity and innovation capacity of the firm. The Chief Human Resources Officer maintains a focus on building a resilient, high-performing team capable of meeting the evolving demands of the biopharmaceutical industry.

Gregory Kuzma, the Senior Vice President, Chief Information Officer at Curia, directs the digital transformation and information technology infrastructure of the organization. Overseeing the security and integration of data systems across research and manufacturing facilities, the Senior Vice President, Chief Information Officer ensures the integrity of sensitive pharmaceutical data. Gregory Kuzma architects scalable cloud solutions and advanced analytics platforms that drive operational efficiency and support data-driven decision-making. By managing the cybersecurity posture of the firm, the Senior Vice President, Chief Information Officer protects intellectual property and ensures compliance with global regulatory requirements. This leadership role involves collaborating with other C-suite executives to align technology investments with business growth objectives. Through the modernization of IT systems, Kuzma enables seamless communication and collaboration across international operations. The Senior Vice President, Chief Information Officer maintains a focus on leveraging emerging technologies to enhance the speed and accuracy of drug development and manufacturing processes.